Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Erlotinib”

733 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 733 results

Early research (Phase 1)Study completedNCT00047762
What this trial is testing

Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Genentech, Inc.
Early research (Phase 1)Study completedNCT00729742
What this trial is testing

Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Who this might be right for
Carcinoma, Non-small Cell Lung
Merck Sharp & Dohme LLC 49
Testing effectiveness (Phase 2)Study completedNCT00043823
What this trial is testing

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Who this might be right for
Lung Cancer
M.D. Anderson Cancer Center 41
Early research (Phase 1)Ended earlyNCT01288430
What this trial is testing

DS-2248 in Participants With Advanced Solid Tumors

Who this might be right for
Solid TumorsNon-small Cell Lung Carcinoma
Daiichi Sankyo 60
Testing effectiveness (Phase 2)Ended earlyNCT00387894
What this trial is testing

Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Who this might be right for
Adult Brain Tumors
Michael Prados 6
Early research (Phase 1)Study completedNCT00085553
What this trial is testing

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

Who this might be right for
Solid Neoplasm
National Cancer Institute (NCI) 29
Testing effectiveness (Phase 2)WithdrawnNCT02044601
What this trial is testing

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

Who this might be right for
Lung Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT00442507
What this trial is testing

Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

Who this might be right for
Esophageal NeoplasmsEsophageal Diseases
Washington University School of Medicine 6
Testing effectiveness (Phase 2)Ended earlyNCT00783471
What this trial is testing

Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Hellenic Cooperative Oncology Group 51
Not applicableStudy completedNCT01790217
What this trial is testing

An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 52
Testing effectiveness (Phase 2)Ended earlyNCT00459901
What this trial is testing

Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Peter Kozuch 13
Large-scale testing (Phase 3)UnknownNCT00955695
What this trial is testing

Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
National Cancer Center, Korea 242
Testing effectiveness (Phase 2)Study completedNCT00550537
What this trial is testing

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Vanderbilt-Ingram Cancer Center 116
Testing effectiveness (Phase 2)Study completedNCT00126581
What this trial is testing

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Who this might be right for
Lung AdenocarcinomaLung Adenosquamous CarcinomaMalignant Pericardial Effusion+4 more
National Cancer Institute (NCI) 188
Testing effectiveness (Phase 2)Ended earlyNCT01455389
What this trial is testing

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Who this might be right for
Lung Cancer
Genprex, Inc. 25
Not applicableUnknownNCT02328391
What this trial is testing

STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE

Who this might be right for
Carcinoma, Squamous Cell
Grupo Gallego de Cancer de Pulmon 51
Testing effectiveness (Phase 2)Study completedNCT00088946
What this trial is testing

Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer

Who this might be right for
Bladder Cancer
Jonsson Comprehensive Cancer Center 17
Testing effectiveness (Phase 2)Study completedNCT01222689
What this trial is testing

Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Who this might be right for
Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage III Pancreatic Cancer+1 more
National Cancer Institute (NCI) 46
Not applicableStudy completedNCT02595450
What this trial is testing

A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 299
Early research (Phase 1)Study completedNCT02154737
What this trial is testing

Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Tony Reid, M.D., Ph.D. 24
Next Page